

# **DRUG PRIOR AUTHORIZATION COMMITTEE**

**September 20, 2012**

James C. Kirkpatrick State Information Center

600 West Main Street

Jefferson City, MO

## **TENTATIVE AGENDA**

10:00 - 10:05	Welcome, Announcements and Introductions	Acting Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:15	Pharmacy Program/ Budget Update	Rhonda Driver/ Andrew Haslag
11:15 - 11:20	DUR Update	Rhonda Driver
	<b><u>Old Business</u></b>	
11:20 – 11:30	<b>A.</b> Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
	<b><u>New Business</u></b>	
11:30 – 11:45	<b>B.</b> <b><u>Proposed Actions- New Drug/Product Reviews</u></b> (See website and Attached Summary) <ol style="list-style-type: none"><li><b>i. Open Access</b></li><li><b>ii. Clinical Edit/Step Therapy</b></li><li><b>iii. PDL Products</b></li><li><b>iv. Prior Authorization</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ol>	Rhonda Driver
11:45 – 1:00	<b>C.</b> <b><u>Preferred Drug List (PDL)</u></b> <ol style="list-style-type: none"><li><b>i. ACE Inhibitors</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>ii. ACE Inhibitors Diuretic Combinations</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>iii. ACE Inhibitor / Calcium Channel Blocker</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>iv. Alpha-Glucosidase Inhibitors</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>v. Alzheimer's Agents</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ol>	

- vi. **Angiotensin Receptor Blocker**
  - Discussion
  - Public Hearing
  - Decision
- vii. **Angiotensin Receptor Blocker Diuretic Combinations**
  - Discussion
  - Public Hearing
  - Decision
- viii. **Anti-Diabetic Combination Agents**
  - Discussion
  - Public Hearing
  - Decision
- ix. **Antihyperuricemic Agents**
  - Discussion
  - Public Hearing
  - Decision
- x. **Biguanides**
  - Discussion
  - Public Hearing
  - Decision
- xi. **Bile Salts**
  - Discussion
  - Public Hearing
  - Decision
- xii. **Bone Ossification Suppression Agents and Calcitonins**
  - Discussion
  - Public Hearing
  - Decision
- xiii. **Cryopyrin Associated Periodic Syndrome (CAPS) Agents**
  - Discussion
  - Public Hearing
  - Decision
- xiv. **Direct Renin Inhibitor and Combinations**
  - Discussion
  - Public Hearing
  - Decision
- xv. **Electrolyte Depleters**
  - Discussion
  - Public Hearing
  - Decision
- xvi. **Fibromyalgia Agents**
  - Discussion
  - Public Hearing
  - Decision
- xvii. **Herpes Antivirals**
  - Discussion
  - Public Hearing
  - Decision
- xviii. **DMARDS / Immunomodulators**
  - Discussion
  - Public Hearing
  - Decision
- xix. **Inhaled Antibiotics**
  - Discussion
  - Public Hearing
  - Decision

- xx. Intranasal Antihistamines**
  - Discussion
  - Public Hearing
  - Decision
- xxi. Leukotriene Modifiers**
  - Discussion
  - Public Hearing
  - Decision
- xxii. Niacin Preparations and Combinations**
  - Discussion
  - Public Hearing
  - Decision
- xxiii. Low Sedating Antihistamines**
  - Discussion
  - Public Hearing
  - Decision
- xxiv. Low Sedating Antihistamine / Decongestant Combos**
  - Discussion
  - Public Hearing
  - Decision
- xxv. Macrolides-Adult / Pediatric**
  - Discussion
  - Public Hearing
  - Decision
- xxvi. Meglitinides**
  - Discussion
  - Public Hearing
  - Decision
- xxvii. Multiple Sclerosis Agents**
  - Discussion
  - Public Hearing
  - Decision
- xxviii. Narcotics: Long Acting**
  - Discussion
  - Public Hearing
  - Decision
- xxix. Nasal Steroids**
  - Discussion
  - Public Hearing
  - Decision
- xxx. NSAID Agents**
  - Discussion
  - Public Hearing
  - Decision
- xxxi. Ophthalmic Antihistamines**
  - Discussion
  - Public Hearing
  - Decision
- xxxii. Ophthalmic Mast Cell Stabilizers**
  - Discussion
  - Public Hearing
  - Decision
- xxxiii. Ophthalmic Prostaglandin Agonists**
  - Discussion
  - Public Hearing
  - Decision
- xxxiv. Ophthalmic Quinolones**
  - Discussion
  - Public Hearing
  - Decision
- xxxv. Pancreatic Enzymes**
  - Discussion
  - Public Hearing
  - Decision

- xxxvi. **Pulmonary Hypertension Agents – Inhaled / Injectable**
  - Discussion
  - Public Hearing
  - Decision
- xxxvii. **Pulmonary Hypertension Agents - Oral**
  - Discussion
  - Public Hearing
  - Decision
- xxxviii. **Quinolones – Systemic**
  - Discussion
  - Public Hearing
  - Decision
- xxxix. **2<sup>nd</sup> Generation Sulfonylureas**
  - Discussion
  - Public Hearing
  - Decision
- xl. **Self-Injectable Epinephrine Agents**
  - Discussion
  - Public Hearing
  - Decision
- xli. **Serotonin Receptor Agonists (Triptans)**
  - Discussion
  - Public Hearing
  - Decision
- xlii. **Tetracyclines**
  - Discussion
  - Public Hearing
  - Decision
- xliii. **Thiazolidinediones**
  - Discussion
  - Public Hearing
  - Decision
- xliv. **Topical Agents for Psoriasis**
  - Discussion
  - Public Hearing
  - Decision
- xliv. **Topical Retinoids**
  - Discussion
  - Public Hearing
  - Decision
- xlvi. **Topical Steroids: Low, Medium, High, Very High**
  - Discussion
  - Public Hearing
  - Decision
- xlvii. **Tramadol-Like Agents**
  - Discussion
  - Public Hearing
  - Decision
- xlviii. **Ulcerative Colitis Agents – Oral**
  - Discussion
  - Public Hearing
  - Decision
- xlix. **Ulcerative Colitis Agents – Rectal**
  - Discussion
  - Public Hearing
  - Decision
- I. **Vaginal Antibiotics**
  - Discussion
  - Public Hearing
  - Decision

- D. **Preferred Drug List**
- i. Process Discussion
  - ii. Therapeutic classes/to be announced at meeting

1:00

**LUNCH**

1:15-1:30

**Program Utilization Information-ACS Update**

Rhonda Driver/  
Jennifer Kemp-Cornelius

1:30-1:50

**Other Business**

- "Top 25" Drugs by Cost
- Clinical Edit Summary Report
- Call Center Statistics

*Informal comments will be accepted from members of the audience at various points in the agenda.  
Times noted are approximate, Agenda may move more quickly*

**Executive Session**

1:50-1:55

Minutes Review

Discussion/Approval

1:55-2:30

Case Reviews

Jenna Twehus

**NEXT MEETING: December 20, 2012**